Comparison of Bivalirudin Versus Heparin for Anticoagulation During Extracorporeal Membrane Oxygenation
Hasegawa D, Sato R, Prasitlumkum N, Nishida K, Keaton B, Acquah SO, Im Lee Y (2022) · ASAIO Journal · n=0
Perfil del estudio
- Diseño
- systematic review and random-effects meta-analysis of 11 observational studies (Embase, Cochrane Central, MEDLINE)
- Tamaño de la muestra (n)
- —
- Intervención
- Bivalirudin anticoagulation in ECMO patients
- Comparador
- Heparin anticoagulation in ECMO patients
- Punto final primario
- Short-term mortality
- Resultado primario
- Bivalirudin associated with significantly lower short-term mortality (OR 0.71, 95% CI 0.55-0.92, p=0.01, I²=7%) compared with heparin in ECMO patients
- Duración del seguimiento
- Hospital discharge / short-term
- PMID
- 36194483
Hallazgos clave
- Mortality signal in favor of bivalirudin (OR 0.71, p=0.01)
- Low heterogeneity (I²=7%) supports robustness
- Adds quantitative mortality endpoint to ECMO anticoagulant literature
- Random-effects model used to account for clinical heterogeneity
- Calls for prospective RCT confirmation
Limitaciones
- All included studies observational
- Selection bias - bivalirudin often reserved for HIT or bleeding patients
- Variable anticoagulation monitoring strategies across studies
- Cannot establish causation
- Not applicable to whole-leech hirudotherapy
Implicaciones clínicas
Hasegawa 2022 contributes a positive mortality signal to the broader bivalirudin ECMO evidence base. For ASH, the meta-analysis demonstrates how the synthetic thrombin inhibitor pathway generates emerging mortality signals under retrospective synthesis, structurally separate from the K040187 device-leech US clinical practice. The mortality finding warrants RCT confirmation.
Estudios relacionados
Prospective Randomized Pilot Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric Extracorporeal Membrane Oxygenation
McMichael A, Weller J, Li X, Hatton L, Zia A, Raman L (2024)
Efficacy of Bivalirudin for Therapeutic Anticoagulation in COVID-19 Patients Requiring ECMO Support
Trigonis R, Smith N, Porter S, Anderson E, Jennings M, Kapoor R, Hage C, Moiz S, Garcia J, Rahman O (2021)
Bivalirudin versus heparin anticoagulation in patients receiving extracorporeal membrane oxygenation
Huang D, Guan Q, Qin J, Shan R, Wu J, Zhang C (2022)
Heparin-based versus bivalirudin-based anticoagulation in pediatric extracorporeal membrane oxygenation: A systematic review
Valdes CA, Sharaf OM, Bleiweis MS, Jacobs JP, Mumtaz M, Sharaf RM, Jeng EI, Peek GJ (2023)